← Back to Search

Other

JNJ-77242113 for Plaque Psoriasis (SUMMIT Trial)

Phase 2
Waitlist Available
Research Sponsored by Janssen Research & Development, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to week 24

Summary

This trial is testing a new pill called JNJ-77242113 to see if it can better treat moderate-to-severe plaque psoriasis. The pill aims to calm the immune system, which helps reduce skin problems caused by psoriasis.

Eligible Conditions
  • Plaque Psoriasis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to week 24
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to week 24 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Score at Week 16
Secondary study objectives
Change from Baseline in Body Surface Area (BSA) at Week 16
Change from Baseline in PASI Total Score at Week 16
Number of Participants with Adverse Events (AEs)
+5 more

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Group 2: JNJ-77242113 Dose 2Experimental Treatment1 Intervention
Participants will receive JNJ-77242113 Dose 2 as delayed release tablets orally once daily from Week 0 through Week 16.
Group II: Group 1: JNJ-77242113 Dose 1Experimental Treatment1 Intervention
Participants will receive JNJ-77242113 Dose 1 as delayed release tablets orally once daily from Week 0 through Week 16.
Group III: Group 3: PlaceboPlacebo Group1 Intervention
Participants will receive oral dose of matching placebo once daily from Week 0 through Week 16.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
JNJ-77242113
2022
Completed Phase 2
~640

Find a Location

Who is running the clinical trial?

Janssen Research & Development, LLCLead Sponsor
1,004 Previous Clinical Trials
6,398,217 Total Patients Enrolled
Janssen Research & Development, LLC Clinical TrialStudy DirectorJanssen Research & Development, LLC
770 Previous Clinical Trials
3,973,957 Total Patients Enrolled
~27 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top